Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02933502 · ClinicalTrials.gov registry record · Phase 2
Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product
A Phase 2 study of Scalp Psoriasis, sponsored by Sun Pharmaceutical Industries.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT02933502: Completed Phase 2 study of Scalp Psoriasis, sponsored by Sun Pharmaceutical Industries.
NCT02933502 is a Phase 2 study of Scalp Psoriasis that has completed, run by Sun Pharmaceutical Industries. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02933502, a Phase 2 study of Scalp Psoriasis, has completed, sponsored by Sun Pharmaceutical Industries.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis
Primary Outcome
Hypothalamic Pituitary Adrenal (HPA) Axis Response to stimulation
Conditions Studied
Interventions
- DRUG DSXS topical product
Study Locations (1)
New York
- Taro Pharmaceuticals USA Inc. - Hawthorne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2016-07-11 |
| Est. Completion | 2018-01-02 |
| Phase | Phase 2 |
What the finished NCT02933502 record still lists
NCT02933502 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Scalp Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which DSXS topical product is the first listed.
NCT02933502 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02933502 about?
NCT02933502 is a clinical study titled "Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product". An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis
What is the current status of trial NCT02933502?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2016-07-11. Estimated completion is 2018-01-02.
What conditions does trial NCT02933502 study?
This clinical trial studies the following conditions: Scalp Psoriasis.
What interventions are being tested in trial NCT02933502?
The interventions under investigation include: DSXS topical product (DRUG).
Who is sponsoring clinical trial NCT02933502?
This trial is sponsored by Sun Pharmaceutical Industries, which has 48 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02933502 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Scalp Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02933502's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI